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Latent tuberculosis infection (LTBI) is evidence of immunological control of tuberculosis. Dormancy survival regulator (DosR)
regulon-encoded proteins may have a role in the maintenance of LTBI. T cell responses to Rv1733c, Rv0081, Rv1735c, and Rv1737c
DosR regulon-encoded proteins were found to be most frequent among household contacts of TB cases from Uganda compared
to other DosR proteins, but antibody responses were not described. We characterized antibody responses to these proteins in
individuals from Uganda. Antibodies to Rv1733c, Rv0081, Rv1735c, and Rv1737c DosR regulon-encoded proteins were measured in
68 uninfected individuals, 62 with LTBI, and 107 with active pulmonary tuberculosis (APTB) cases. There were no differences in
the concentrations of antibodies to Rv0081, Rv1735c, and Rv1737c DosR regulon-encoded proteins between individuals with LTBI
and APTB and those who were uninfected. LTBI was associated with higher concentrations of antibodies to Rv1733c in female
participants [adjusted geometric mean ratio: 1.812, 95% confidence interval (CI): 1.105 2.973, and 𝑝 = 0.019] but not in males (𝑝
value for interaction= 0.060). Antibodies to the fourDosR regulon-encoded proteins investigatedmaynot serve as good biomarkers
of LTBI in the general population. More of theM.tb proteome needs to be screened to identify proteins that induce strong antibody
responses in LTBI.
1. Introduction
Mycobacterium tuberculosis (M.tb) is the causative agent of
tuberculosis (TB), a disease that affects millions of people
worldwide. In 2015, there were approximately 10.4 million
cases of TB and 1.5 million deaths from it [1]. This disease
is transmitted via inhalation of aerosolized bacilli and repli-
cates within alveolar macrophages in lung tissue [2]. Once
infected, themajority of healthy individuals are able to recruit
immune cells to the affected sites and encase the invading
mycobacteria in a structure known as a granuloma.This rich
cellular environment favours activation of macrophages and
killing of phagocytosed M.tb through the release of reactive
oxygen species and nitrogen intermediates [3]. Despite these
adverse conditions, tubercle bacilli may sometimes persist
and remain in a nonreplicative state called latency [4]. In
this state they remain dormant but can reactivate and cause
disease when immune suppression occurs [5]. Only 5–10%
of immunocompetent individuals with latent tuberculosis
infection (LTBI) ever progress to active disease in their
lifetime [6]. This suggests an ability of the majority of people
with LTBI to effectively control M.tb infection. Current
knowledge suggests that bacterial suppression principally
involves T cell mediated immunity [5]. Little is known about
humoral immunity in LTBI because B cells and antibodies
are thought to have a negligible role in the control of TB
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infection [7]. However, antibody responses are observed
in LTBI [8, 9]. Recent findings by Lu et al. show that
antibodies from individuals with LTBI improve macrophage
killing of engulfed bacilli [10]. In addition to these functional
properties, antibodies could serve as important biomarkers of
M.tb infection.
During latency, tubercle bacilli live in a microenviron-
ment of reduced nutrients, hypoxia [11, 12], and low concen-
trations of nitric oxide. Simulation of this state in in vitro
experiments has shown increasedMycobacterium expression
of 48 proteins encoded in the dormancy survival regula-
tor (DosR) regulon [3]. These findings suggest that DosR
regulon-encoded proteinsmay have a role in themaintenance
of latency. Studies with human subjects have demonstrated
strong cell mediated responses to DosR regulon-encoded
proteins in individuals with LTBI that exceed those from
TB cases and uninfected controls [12, 13]. This suggests that
immune responses to DosR regulon-encoded proteins might
be used as specific biomarkers of LTBI.
The currently used tests for the diagnosis of LTBI are the
tuberculin skin test (TST) and the interferon gamma release
assays [5]. Despite their wide use, both of these tests are
unable to differentiate active TB from LTBI [14]. The use of
anti-DosR immune responses for the diagnosis of LTBI could
help overcome this limitation. Since these proteins are able
to induce cell mediated responses in the latent state of M.tb
infection, they may also induce humoral immune responses.
If shown to be the case, antibodies against DosR regulon-
encoded proteins could have a potential use as biomarkers of
LTBI. Without the need for the isolation of cells or a period
of cell stimulation, the measurement of these antibodies in
serum or plasma may present a cheaper, easier, and faster
means of diagnosing LTBI compared to the measurement of
cell mediated responses.
Several studies have reported the use of M.tb proteins,
such as the 38-kDa [15–18] protein as well as early secre-
tory antigen target- (ESAT-) 6 [15, 17, 19], culture filtrate
protein- (CFP-) 10 [17, 19], and MTB48 proteins [18, 19]
for serodiagnosis of active pulmonary tuberculosis (APTB).
However, very few studies have identified proteins that can
be used for the serodiagnosis of LTBI. A study by Davidow
et al. [15] reported a lack of antibodies in LTBI agreeing
with the widely held notion that humoral responses are
only induced during active TB and not during latency.
However, there are studies that contradict this. Research by
Eleftheriadis et al. [20] described the use of antibodies to
lipoarabinomannan (LAM) in the diagnosis of latent TB in
haemodialysis patients as well as healthy volunteers with no
clinical evidence of active TB. The authors went on to show
that LTBI positivity by anti-LAM antibodies correlated well
with TST positivity in all these individuals. Furthermore, a
study Chen et al. showed that individuals with LTBI had
higher antibody responses to Rv1985c compared to BCG
vaccinated individuals who had no known contact with
TB cases [9]. Additionally, research from our own group
has described increased levels of antimycobacterial specific
plasmablasts and memory B cells among healthy individuals
with likely latent TB infection [8]. Although the results of all
these studies have not been reproduced in other populations,
they do give us reason to suggest that LTBI could induce
antibody responses to mycobacterial antigens. The search for
M.tb proteins with possible serodiagnostic value for LTBI is
therefore still warranted.
A study by Black et al. [21] was able to describe interferon
gamma responses to 51 DosR regulon-encoded proteins
in LTBI positive, human immunodeficiency virus- (HIV-)
negative adult household contacts of APTB cases from
The Gambia, Uganda, and South Africa. It showed four
DosR regulon-encoded proteins, Rv1733c, Rv0081, Rv1735c,
and Rv1737c were most frequently recognized in latent TB
infected HHCs from Uganda compared to other DosR pro-
teins, with percentages of 79%, 70%, 61%, and 50%, respec-
tively. The DosR protein, Rv1733c, has also been reported to
be frequently recognized by T cell responses in individuals
with LTBI from Germany [13] and Netherlands [12]. A more
recent multicentre study of individuals from sub-Saharan
Africa showed Rv1733c, Rv1735c, and Rv1737c were among
the proteins that induced T cell responses in individuals
with LTBI that were higher than those induced in active TB
[22]. One could suppose that these findings reflect increased
expression of these proteins in LTBI.
Although all of the studies mentioned above character-
ized cell mediated responses to these proteins, they did not
look at humoral responses.TheT cells induced by these DosR
proteins may provide help to B cells and promote antibody
responses. The detection of such antibodies in peripheral
blood could help in serodiagnosis of LTBI. In this present
study, we investigated IgG antibody responses against M.tb
H37Rv proteins, Rv1733c, Rv0081, Rv1735c, and Rv1737c in a
Ugandan cohort comprising healthy uninfected individuals,
those with LTBI and APTB cases. Our main objective was
to determine whether these antibodies could be used as
biomarkers of LTBI.
2. Materials and Methods
2.1. Study Design and Population. This was a cross-sectional
study nested in a TB household contact study based in
Kampala, Uganda [23]. It was exploratory in nature and
the number of individuals investigated was limited to those
whose samples were available from the larger study. A total
of 237 study participants were included in our investiga-
tions. They came from Kisenyi and Kitebi municipalities of
Kampala district. This number is comprised of 68 unin-
fected individuals, 62 with LTBI, and 107 APTB cases. They
were defined as having LTBI if they had both a positive
QuantiFERON-TB Gold In-Tube (QFT) test and TST result
with no signs or symptoms of active TB and were defined
as being uninfected if they had both a negative QFT and
TST result. Individuals with APTB had a positive acid-fast
bacilli result after performing sputum smear microscopy and
had either just began treatment or had been on treatment for
less than 4 weeks. Stored samples collected between 2010 and
2011 were used for these investigations.These included serum
samples from the uninfected individuals and those with LTBI
and QFT nil control supernatants from the APTB cases. The
nil control QFT supernatants were used because of a lack of
stored sera or plasma from these individuals.
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2.2. Ethical Clearance. All samples were obtained from study
participants following written informed consent. This study
obtained ethical clearance to carry out this research from the
Makerere University School of Medicine Research & Ethics
Committee and the Uganda National Council for Science &
Technology.
2.3. Antigens. Antibody responses to Rv1733c, Rv0081,
Rv1735c, and Rv1737c had not been studied before in any
similar population and for this reason we also chose to look
at antibodies against a well-characterizedM.tb protein, CFP-
10/ESAT-6 fusion protein [18, 19], in the same individuals as
a control.
Recombinant DosR regulon-encoded proteins, Rv1733c,
Rv0081, Rv1735c, and Rv1737c, and CFP-10/ESAT-6 fusion
protein were kindly provided by Professor TomH. M. Otten-
hoff, Leiden University Medical Centre. These proteins were
expressed in Escherichia coli BL21(DE3) and purified, using
methods previously described by the Ottenhoff group [21].
They were then freeze-dried and shipped to Uganda where
they were reconstituted in phosphate-buffered saline (PBS)
containing 1% dimethyl sulfoxide for use in antibody assays.
2.4. Procedure of IgG Antibody ELISA. Immunolon 4 HBX
microtiter plates (Thermoscientific, USA) were coated with
5 𝜇g/well of antigen or 0.1% skimmed milk (control for
nonspecific binding) in carbonate-bicarbonate buffer (pH
9.6) at 4∘C overnight. Additionally, each plate was coated
with eight, twofold serial dilutions of human IgG reference
standard (Genscript) at a top concentration of 625 ng/ml.
Following overnight incubation, the plates were washed four
times with PBS (pH 7.4) containing 0.05% Tween 20 (PBS-
T). The plates were then blocked with 1% skimmed milk
in PBS-T for 2 hours at room temperature. A dilution of 1
in 50 was made of each serum/supernatant sample in 0.1%
skimmedmilk PBS-T (assay buffer) and then 50𝜇l was added
to antigen-coated and control wells. A pooled sample of
nil control QFT supernatants from 40 active TB cases was
included on each plate as a positive control for the assay.
All samples and positive controls were assayed in duplicate
to minimize effects of random variations in volumes due
to pipetting errors. After an incubation of 2 hours at room
temperature, the wells were washed as before and incubated
with 50𝜇l/well polyclonal rabbit anti-human IgG conjugated
with horseradish peroxidase (Dako, Denmark) at 0.5 𝜇g/ml
for another hour at the room temperature. Plates were then
washed and enzyme activity detected by incubation with
100 𝜇l/well o-phenylenediamine (Sigma) containing hydro-
gen peroxide for 15 minutes. The reaction was stopped by
addition of 25 𝜇l/well 2mol/litre sulfuric acid and thereafter
the optical density (OD) measured at a test wavelength of
490 nm and a reference wavelength of 630 nm in an ELISA
plate reader (Biotek).TheODs from the human IgG standard
concentrations on every plate were used to generate standard
reference curves for use in conversion of sample ODs to
antibody concentrations in ng/ml. The concentrations of the
control wells were subtracted from the test antigen wells to
eliminate background antibody levels.We thenmultiplied the
result by the sample dilution factor of 50.
2.5. Data Analysis. Data was analysed using Stata release
14.0 statistical package (Statacorp LP, College Station, TX,
USA). Our main exposure was M.tb infection status while
our outcomes were antibody responses. Other exposures
or potential confounders considered were age, gender, HIV
infection status, and socioeconomic status (SES). The latter
was defined by the quality of household external structure
and roofing as well as the kind of lighting employed [23]. Age
was not stratified but was left as a continuous variable during
the analyses.
The crude analysis involved the use of the chi-squared
test to check for associations between potential confounders
and M.tb infection. Further crude analysis involved the use
of the Kruskal Wallis tests to check for differences in the
distribution of IgG antibodies across groups of uninfected
individuals, those with LTBI and APTB cases. The antibody
data was then transformed to natural log (concentration
+1) and linear regression analysis with bootstrap estimated
confidence intervals was used to test for associations between
M.tb infection status and the antibody responses [24] while
adjusting for the confounders, age, gender, andHIV infection
status. The results were then back-transformed to provide
geometric mean ratios. We used this approach because all
of our antibody data did not follow the normal distribution
and there was still evidence of nonnormality even after log
transformation.
3. Results
3.1. Demographic Characteristics. The study participants
included individuals of varied age, gender, HIV infection
status, and SES.These characteristics, alongwith the results of
chi-square tests of associations with M.tb infection state, are
shown in Table 1. Uninfected individuals were younger than
those with LTBI and APTB. This may be explained in part
by the selection criteria for APTB cases, as these individuals
were only enrolled into the study if they were beyond the
age of 18 years and may therefore have biased this group
of individuals. The same criterion was not imposed upon
those who were uninfected or had LTBI. The observation
that individuals with LTBI were older than those who were
uninfected may reflect increasing risk of exposure to M.tb
with age [25]. There were more males than females with
APTB and more females than males with LTBI, reflecting
the disparity in TB infection rates across gender [26]. There
weremoreHIVpositive individuals among theAPTB cases in
comparison to the other groups. This is likely due to the fact
that HIV coinfection is a known risk factor for acquisition
of TB disease [6]. We found no association between SES and
M.tb infection status.
3.2. Factors Associated with Concentrations of IgG Antibod-
ies to DosR Proteins and CFP-10/ESAT-6. We made crude
comparisons of the concentrations of IgG antibodies to the
different proteins across groups of uninfected individuals,
those with LTBI and APTB cases using the Kruskal–Wallis
test. With the exception of anti-Rv1737c antibodies, there
was evidence of differences in the concentrations of all the
antibodies across the three groups (Figure 1).
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Table 1: Study participant characteristics.
Characteristic Uninfected (𝑛 = 68) LTBI (𝑛 = 62) Active PTB (𝑛 = 107) 𝑝 value1
Mean age & range (years) 16 (1, 66) 24 (1, 66) 30 (18, 53) <0.0001
Females 39 (57.4%) 41 (65%) 44 (41.1%) 0.006
HIV positive 6 (8.8%) 5 (7.9%) 42 (39.3%) <0.0001
Low SES2 34 (50.8%) 32 (51%) 58 (61%) 0.309
LTBI = latent tuberculosis infection, SES = socioeconomic status, and APTB = active pulmonary tuberculosis.
1
𝑝 values are from chi-square tests of associations.
2Individuals were either of low or medium SES.
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Figure 1: Scatter dot plots showing IgG antibody concentrations. The tuberculin skin test (TST) and the QuantiFERON TB Gold In-Tube
(QFT) were used to determine if individuals were uninfected or had latent tuberculosis infection (LTBI). Sputum smear microscopy was used
to define APTB cases.The horizontal bars shown are median concentrations of IgG antibodies in each group.The 𝑝 values shown correspond
to results from Kruskal–Wallis test.
Linear regression analysis was used to test for associations
between M.tb infection status and antibody responses to the
DosR proteins (Table 2). The uninfected individuals were the
baseline comparison group. Our hypothesis was that LTBI
would be associated with higher concentrations of antibodies
to the four DosR regulon-encoded proteins compared to
the uninfected individuals. Results from unadjusted analysis
showed no associations between LTBI and antibodies to
the four DosR regulon-encoded proteins. APTB appeared
to be associated with higher anti-Rv0081 and anti-Rv1735c
antibodies. There was a similar trend with anti-Rv1737c
antibodies but there was only marginal evidence to this
effect. After adjusting for the effects of age, gender, and
HIV infections status, we still did not see any associations
between LTBI and the antibodies to the DosR proteins.
There was no longer an association between APTB and anti-
Rv1735c antibodies and the evidence for a positive association
betweenAPTBand antibodies toRv0081was not as strong.As
expected from prior literature [18, 19], we found that APTB
was associated with higher concentrations of antibodies to
CFP-10/ESAT-6 compared to uninfected individuals in both
unadjusted and adjusted analyses. There was no evidence
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Table 2: Associations betweenMycobacterium tuberculosis infection status and concentrations of IgG antibodies to DosR proteins and CFP-
10/ESAT-6 in study participants.
Antibody/factor Crude geometric mean ratio (95% CI) 𝑝 value Adjusted geometric mean ratio (95% CI)1 𝑝 value
Anti-Rv1733c antibodies
Uninfected 1 1
LTBI 1.374 (0.915–2.063) 0.125 1.240 (0.792–1.942) 0.346
APTB 1.346 (0.916–1.974) 0.131 1.370 (0.904–2.078) 0.138
Anti-Rv0081 antibodies
Uninfected 1 1
LTBI 1.437 (0.761–2.714) 0.264 1.382 (0.700–2.727) 0.343
APTB 1.790 (1.007–3.184) 0.047 1.707 (0.956–3.046) 0.071
Anti-Rv1735c antibodies
Uninfected 1 1
LTBI 1.203 (0.774–1.869) 0.411 1.059 (0.651–1.722) 0.818
APTB 1.529 (1.058–2.210) 0.024 1.333 (0.912–1.949) 0.138
Anti-Rv1737c antibodies
Uninfected 1 1
LTBI 1.147 (0.704–1.868) 0.581 1.122 (0.650–1.938) 0.680
APTB 1.479 (0.966–2.264) 0.072 1.352 (0.801–2.282) 0.259
Anti-CFP-10/ESAT-6 antibodies
Uninfected 1 1
LTBI 1.162 (0.682–1.981) 0.580 1.019 (0.567–1.829) 0.951
APTB 2.199 (1.415–3.418) <0.001 2.020 (1.279–3.190) 0.003
LTBI = latent tuberculosis infection; APTB = active pulmonary tuberculosis.
1Regression analyses were performed with bootstrap confidence intervals generated from 1000 replicate samples of data.The data was from 68 individuals who
were uninfected, 62 with LTBI, and 105 with APTB. Adjusting was done for age, gender, and HIV infection status. Analysis was performed on log transformed
values and back-transformed to provide geometric mean ratios.
of any difference in anti-CFP-10/ESAT-6 antibodies between
uninfected individuals and those with LTBI which is also
consistent with prior literature [15].
Therewas a higher concentration of antibodies to Rv1733c
[adjusted geometric mean ratio (adjusted GMR): 1.013, 95%
confidence interval (CI): 1.000–1.027, and 𝑝 = 0.05], Rv1735c
(adjusted GMR: 1.016, 95% CI: 1.002–1.031, and 𝑝 = 0.022),
and CFP-10/ESAT-6 (adjusted GMR): 1.015, 95% CI: 1.002–
1.028, and 𝑝 = 0.027) with increasing age. This observation
may be a result of increasing risk of exposure to M.tb
with age [25]. We found that HIV infection was associated
with lower concentrations of antibodies to Rv1733c (adjusted
GMR: 0.498, 95% CI: 0.286–0.870, and 𝑝 = 0.014], Rv1735c
(adjusted GMR: 0.688, 95% CI: 0.477–0.993, and 𝑝 =
0.046), and CFP-10/ESAT-6 (adjusted GMR: 0.496, 95% CI:
0.327–0.754, and 𝑝 = 0.001). This result may reflect the
suppressive effects of HIV infection on B cell immunity [27].
As discussed previously, HIV is a known risk factor for TB
disease progression [6]. We performed a test of interaction
to see if HIV infection could be modifying the effect ofM.tb
infection on the antibody responses to the DosR proteins but
found no evidence in support of this.
Females had lower concentrations of antibodies to the
CFP-10/ESAT-6 (adjusted GMR: 0.496, 95% CI: 0.453–0.988,
and 𝑝 = 0.043) compared to males. This finding may
reflect gender related differences in the immune response to
pathogens [28]. Gender is known to influence rates of M.tb
infection as well as the rate of progression to TB disease
[29]. According to the WHO, more males than females
are diagnosed with TB [1]. Based on this information, we
performed a test of interaction to seewhether gender could be
modifying the effect ofM.tb infection on antibody responses.
We found evidence to show that this was the case for antibody
responses to Rv0081 (𝑝 value for interaction = 0.040) and
marginal evidence of a similar interaction with antibody
responses to Rv1733c (𝑝 value for interaction = 0.060). We
stratified the analysis of these two antibodies according to
gender and found that LTBI was associated with significantly
higher concentrations of antibodies to Rv1733c among female
participants (Table 3) but not in their male counterparts.
We found marginal evidence of a similar trend with the
antibodies to Rv0081. We found no association between
APTB and antibodies to both these antigens in either gender.
4. Discussion
This study described antibody responses to Rv1733c, Rv0081,
Rv1735c, and Rv1737c DosR encoded proteins in Ugandan
individuals with LTBI and APTB and those who were unin-
fected. The main finding was that LTBI was associated with
higher anti-Rv1733c antibodies in female participants. Anti-
Rv0081 antibodies were also elevated in these individuals;
however the evidence to show that this was a true increase
was not as strong. There were no associations between M.tb
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Table 3: Associations betweenMycobacterium tuberculosis infection status and concentrations of IgG antibodies to Rv1733c and Rv0081 DosR
proteins in male and female study participants, after adjusting for potential confounders.
Antibody/factor Adjusted geometric mean ratio (95% CI)1 𝑝 value
Anti-Rv1733c antibodies in males
Uninfected 1
LTBI 0.670 (0.292–1.538) 0.345
APTB 1.041 (0.636–1.704) 0.873
Anti-Rv1733c antibodies in females
Uninfected 1
LTBI 1.812 (1.105–2.973) 0.019
APTB 1.718 (0.877–3.369) 0.115
Anti-Rv0081 antibodies in males
Uninfected 1
LTBI 0.631 (0.300–1.331) 0.227
APTB 1.183 (0.674–2.075) 0.558
Anti-Rv0081 antibodies in females
Uninfected 1
LTBI 2.229 (0.833–5.966) 0.111
APTB 2.484 (0.948–6.505) 0.064
LTBI = latent tuberculosis infection and APTB = active pulmonary tuberculosis.
1Regression analyses were performed with bootstrap confidence intervals generated from 1000 replicate samples of data. The data was from 29 uninfected
males, 21 males with LTBI, 62 males with active PTB, 39 uninfected females, 41 females with LTBI, and 43 females with APTB. The 𝑝 value for interaction
was 0.06 for Rv1733c and 0.04 for Rv0081. Adjusting was done for age and HIV infection status. Analysis was performed on log transformed values and back-
transformed to provide geometric mean ratios.
infection status and the antibody responses to Rv1735c and
Rv1737c proteins.
Increased expression of Rv1733c in latency may have
been able to stimulate a specific antibody response in some
individuals with LTBI that could be detected in peripheral
blood. This finding was not entirely surprising because cell
mediated immune responses to Rv1733c, in particular, were
reported to be the most frequent among individuals with
LTBI from four African countries, including Uganda [21].
A study by Leyten et al. [12] in Netherlands also reported
that the majority of individuals with LTBI were shown to
produce strong cell mediated responses to Rv1733c. The
ability of Rv1733c to induce strong cell mediated and antibody
responses in some individuals with LTBI may also be linked
to its immunogenicity. This may equally explain the lack
of significant antibody responses to Rv0081, Rv1735c, and
Rv1737c in LTBI. A study of immune responses to vaccinia
virus showed that promotion of antibody responses by T
cells is antigen specific [30]. This same research showed that
proteins that induce strong T cell responses are associated
with better antibody responses compared to those that do
not. Although Rv0081, Rv1735c, and Rv1737c DosR regulon-
encoded proteins have been shown to induce T cell responses
[21] they may not be sufficiently strong enough to promote
good B cell responses.
The adjusted analyses showed no differences in antibody
responses to any of the DosR regulon-encoded proteins
between APTB cases and uninfected individuals. This con-
trasts with findings from a study by Mattos et al. in Brazil
that reported higher levels of IgG1 antibodies against Rv1733c
in TB cases compared to uninfected controls [31]. Our
participants were from a TB household contact study and as
a result the uninfected individuals may have had exposure
to M.tb. Uganda also has a high burden of TB [1] and this
may translate into higher exposure to TB and higher anti-TB
immune responses at a population level compared to regions
of lower TB prevalence.Thismay have contributed to the lack
of significant differences in anti-DosR antibodies between
our APTB cases and uninfected individuals.
The initial comparisons made using graphs and the
Kruskal Wallis test showed evidence of differences in anti-
Rv1733c, anti-Rv0081, and anti-Rv1735c, antibodies across
the three groups with individuals with LTBI and APTB
appearing to have higher concentrations of these antibodies
compared to the uninfected controls. The unadjusted linear
regression analysis also showed evidence of higher anti-
Rv0081 and anti-Rv1735c antibodies in APTB cases compared
to uninfected controls. The APTB cases and individuals with
LTBI were older than the uninfected controls and so these
initial observations may have been influenced by age and
degree of exposure toM.tb. This is plausible because after age
was included in the regression model, the evidence for these
associations was lost.
This study highlighted gender related difference in the
antibody responses to mycobacterial antigens with females
having lower anti-CFP-10/ESAT-6 antibodies compared to
males. There has been a report of lower PPD specific cell
mediated responses in women compared to men [32] but
we are not aware of any other studies that have reported a
similar difference in the antibody response. We also showed
that gender influences the relationship between LTBI status
and antibody responses to the DosR proteins, Rv1733c and
Journal of Immunology Research 7
Rv0081. Some have suggested that the sexual differences in
TBmay be related to immune response [26]. More study may
be required to decipher the implications of these disparities
and also to discover what their true causes are.
The observation that anti-CFP-10/ESAT-6 antibodies
were higher in APTB cases compared to uninfected controls
concurred with previous literature [18, 19] and helped to
validate our antibody assay. The fact that these antibody
responses were not elevated in individuals with LTBI may
point to a possible use of anti-CFP-10/ESAT-6 antibodies as
markers of disease progression. Longitudinal studies could be
used to investigate this further.
There were some limitations of this study. The fact
that we used QFT nil control supernatants from APTB
cases instead of serum means that comparisons between
antibody concentrations from these individuals and the
other groups where serum samples were used should be
interpreted with caution. These supernatants were harvested
from undiluted whole blood following overnight culture.
This could be sufficient time to allow secretion of antibodies
into supernatants by M.tb specific antibody secreting cells
[33] and could consequently affect antibody concentration.
However, there was no difference in the concentrations of
antibodies to the DosR proteins between APTB cases for
which only QFT nil control supernatants were tested and
uninfected individuals forwhich serum sampleswere used, in
the adjusted analysis.Thismay imply that even if there was an
increase inDosR specific antibodies in theAPTB supernatant
samples, this may not be large enough to lead to a significant
difference in the antibody concentration between the two
sample types. Furthermore, we have observed strong and
statistically significant correlation between concentrations
of anti-mycobacterial antibodies obtained from testing QFT
supernatant and serum sample pairs fromTB household con-
tacts (Supplementary Figure S1 in Supplementary Material
available online at https://doi.org/10.1155/2017/1593143).
On the whole, these results showed that antibodies
against Rv1733c, Rv0081, Rv1735c, andRv1737cDosR regulon-
encoded proteins may not serve as good biomarkers of LTBI.
The fact that the antibody responses to Rv1733c were only
associated with LTBI among females reduces its utility in
the general population. However, Mycobacterium specific
antibody [9, 20] and B cell responses [8] have been detected
in TB latency. There is therefore still a need to identify M.tb
proteins that induce strong antibody responses in LTBI.
Abbreviation
APTB: Active pulmonary tuberculosis
CFP-10/ESAT-6: Culture filtrate protein-10/early
secretory antigen target-6
DosR: Dormancy survival regulator
LTBI: Latent tuberculosis infection
QFT: QuantiFERON-TB Gold In-Tube
SES: Socioeconomic status.
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